Teladoc Misses Q2 Revenue, Slashes Guidance; Stock Plunges 25%
TDOC sits 69% above its 52-week low of $4.4.
Summary
Teladoc reported Q2 revenue of $606.9M, missing the $615.4M consensus, while EPS loss of $0.21 beat estimates by $0.04. The real damage is in guidance: Q3 revenue seen at $569M-$609M, well below the $629.3M consensus, and full-year revenue was cut to $2.362B-$2.447B from a prior $2.481B-$2.576B. BetterHelp cash-pay pressure is accelerating the decline. The stock is down 25% after hours, reflecting the severity of the miss and the lowered outlook. This follows the earlier headline on FY revenue guidance but adds the quarterly details and the magnitude of the guidance cut.
At the time of this announcement, TDOC was trading at $7.45 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $4.40 to $9.89. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Benzinga.